Company news
Cellectar Biosciences, Inc. news in 2021
Cellectar Biosciences, Inc.'s news releases, calls and decks from 2021, newest first.
Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition
December 7, 2021
Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors
November 15, 2021
Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update
November 7, 2021
Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer
November 1, 2021
Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies
October 24, 2021
Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia
August 17, 2021
Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131
August 15, 2021
Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update
August 8, 2021
Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.
July 12, 2021
Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)
July 11, 2021
Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors
June 23, 2021
Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom’s Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 19, 2021
Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update
May 9, 2021
Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico
April 26, 2021
Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates
March 8, 2021
Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update
March 1, 2021
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia
January 26, 2021
Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia
January 11, 2021